Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring
| Autor: | Katherine G, Roth, Isa, Mambetsariev, Ravi, Salgia |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Research Report Lung Neoplasms Brain Neoplasms Class I Phosphatidylinositol 3-Kinases High-Throughput Nucleotide Sequencing Adenocarcinoma of Lung Exons Proto-Oncogene Proteins c-met lung adenocarcinoma B7-H1 Antigen respiratory tract diseases Pyridazines Pyrimidines Piperidines Carcinoma Non-Small-Cell Lung Humans Protein Kinase Inhibitors Aged |
| Zdroj: | Cold Spring Harbor Molecular Case Studies |
| ISSN: | 2373-2873 |
| Popis: | Tyrosine kinase inhibitors (TKIs) have transformed the standard of care in lung cancer. A number of TKIs have been discovered that specifically target oncogenes, including MET receptor tyrosine kinase. Second-generation MET TKIs are showing improved efficacy over first-generation TKIs. Herein, we report a case of a patient with metastatic lung adenocarcinoma harboring a MET exon 14 splice site mutation who has had prolonged disease control by a second-generation MET-TKI tepotinib. A 66-yr-old man was diagnosed with stage IV lung adenocarcinoma. He was started on carboplatin, paclitaxel, and bevacizumab, but had severe toxicity. He was switched to pembrolizumab as his tumor was PD-L1 70%, and molecular testing was not yet performed because of insufficient tissue. A bronchoscopy with endobronchial ultrasound was performed and a MET exon 14 splice site mutation was detected by next-generation sequencing. Upon progression, he was then enrolled in a clinical trial of tepotinib and continues with stable disease for more than 45 cycles and 31 mo. The MET receptor tyrosine kinase and the ligand hepatocyte growth factor (HGF) have been implicated as oncogenes and drivers of non-small-cell lung cancer (NSCLC). Newer MET TKIs including capmatinib and tepotinib more recently showed not only improved localized control and response, but early data suggests intracranial activity as compared to first-generation MET TKIs, both in the front-line and the refractory setting. This is a case report demonstrating an effective duration of response in a patient with widely metastatic lung adenocarcinoma harboring a MET exon 14 mutation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|